The Impact of Dementia and Neurocognitive Disorders on Hypertension Treatment in the Elderly

NCT05845736 | Completed

• 1 other identifier: 2023PI017
• Study Type: observational
• Target: 353
• Locations: 1 country
• Sites: 1

Brief Summary

Neurocognitive disorders and hypertension occur commonly with aging. While, by definition, older adults are at high cardiovascular risk, there is no guideline exist currently on blood pressure management of elderly hypertension. However, studies have shown that in aging adults, high blood pressure helps prevent against cognitive decline, and low blood pressure on antihypertensive drugs could accelerate it. This study aims at investigating if pharmacological treatment of hypertension in the very elderly is influenced by presence and severity of neurocognitive disorders. Our research hypothesis is that the drug management of hypertension in patients 80 years of age or older more is all the less aggressive as the neurocognitive disorders are advanced.

Conditions

Neurocognitive Disorders; Dementia; Hypertension; Aged, 80 and Over

Keywords

Neurocognitive Disorders; Dementia; Hypertension; Aged, 80 and over

Outcome Measures

Primary Outcomes (1)

• number of antihypertensive agents

  among ACEI/ARB2, calcium channel blocker, thiazides and related, central antihypertensive beta blocker

  during inclusion

Secondary Outcomes (3)

• class of antihypertensive medications

  during inclusion

• systolic and diastolic blood pressure

  during inclusion

• orthostatic hypotension

  during inclusion

Study Arms (4)

control group

absence of neurocognitive disorder (ND), Mini-Mental State Examination (MMSE) from 27 to 30 inclusive

Drug: Antihypertensive Agents

mild neurocognitive disorder

MMSE from 21 to 26 inclusive

Drug: Antihypertensive Agents

moderate neurocognitive disorder

MMSE from 11 to 20 inclusive

Drug: Antihypertensive Agents

severe neurocognitive disorder

MMSE less than or equal to 10

Drug: Antihypertensive Agents

Interventions

Antihypertensive Agents DRUG

number of hypertensive drugs

control group; mild neurocognitive disorder; moderate neurocognitive disorder; severe neurocognitive disorder

Eligibility Criteria

• Age: 80 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

All patients aged 80 years or more and hypertensive who received a Comprehensive Geriatric Assessment (including a mini mental state examination) as part of a frailty, memory or oncogeriatric assessment, in day hospital in the geriatric department in University Hospital of Nancy in 2022.

You may qualify if:

• to be 80 years of age
• with history of hypertension and/or on hypertensive drug(s)

You may not qualify if:

• legal protection measure.

Sponsors & Collaborators

• Central Hospital, Nancy, France: lead

Study Sites (1)

Centre Hospitalier Régional Universitaire de Nancy

Nancy, 54000, France

Location

MeSH Terms

Conditions

Neurocognitive Disorders; Dementia; Hypertension

Interventions

Antihypertensive Agents

Condition Hierarchy (Ancestors)

Mental Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Vascular Diseases; Cardiovascular Diseases

Intervention Hierarchy (Ancestors)

Cardiovascular Agents; Therapeutic Uses; Pharmacologic Actions; Chemical Actions and Uses

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: principal investigator

Study Record Dates

• First Submitted: March 26, 2023
• First Posted: May 6, 2023
• Study Start: January 1, 2022
• Primary Completion: January 1, 2022
• Study Completion: December 12, 2022
• Last Updated: May 6, 2023

Record last verified: 2023-05

Locations

FR (1)